NAD+ IV Infusion Protocols

Based on the limited clinical literature available, specific standardized protocols for NAD+ IV infusion are not well-established. The evidence for dosing and administration protocols remains sparse.

Reported Protocol from Clinical Studies

One pilot study documented the following approach:

Duration: 6-hour intravenous infusion
Setting: Clinical monitoring environment
Objective: Investigation of NAD+ metabolome changes

The study examined plasma and urine NAD+ metabolite levels during this extended infusion period, suggesting this duration was considered appropriate for observing physiological effects.

Administration Considerations

The available literature indicates that NAD+ IV infusions:

Require extended infusion times (multiple hours)
Should be administered in clinical settings with appropriate monitoring
May affect various metabolic pathways based on metabolome studies

Evidence Limitations

The current evidence base for NAD+ IV infusion protocols is extremely limited. Most research has focused on oral NAD+ precursors (such as nicotinamide riboside) rather than direct intravenous administration. The tolerability and optimal dosing parameters for IV NAD+ have not been rigorously established through controlled clinical trials.

Important Disclaimer

This information is provided for educational purposes only and does not constitute personalized medical advice. NAD+ IV infusion protocols should only be determined and administered by qualified healthcare providers who can assess individual patient factors, monitor for adverse effects, and adjust treatment parameters as needed. Always consult with a healthcare professional before considering any NAD+ infusion therapy.

NAD+ IV Infusion

Member access required